Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 269 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dextrose in Water Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sugar-replacement Sweeteners, and Blood Sugar Control

NCT01128829
View directory record Official record
Conditions
Obesity
Interventions
Water, Sucralose
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Oct 20, 2026, 5:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

NCT01218867
View directory record Official record
Conditions
Metastatic Cancer, Metastatic Melanoma, Renal Cancer
Interventions
Anti-VEGFR2 CAR CD8 plus PBL, Cyclophosphamide, Aldesleukin, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts

NCT04649541
View directory record Official record
Conditions
Safety
Interventions
MRX-8, Placebo
Drug
Lead sponsor
MicuRx
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Fluid Milk in Attenuating Hyperglycemia and Hypertriglyceridemia After Meal

NCT02894112
View directory record Official record
Conditions
Oral Glucose Tolerance Test, High Fat Tolerance Test
Interventions
non-fat milk, carbohydrate control beverage, caloric control beverage
Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
20 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 20, 2026, 5:03 PM EDT
Terminated Phase 3 Interventional Results available

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

NCT04607668
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
Interventions
Trilaciclib, Placebo
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
24
States / cities
Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes

NCT01886989
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cocoa polyphenols
Dietary Supplement
Lead sponsor
Arpita Basu
Other
Eligibility
21 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 2Phase 3 Interventional

Post Prandial Glucose Control Proof-of-Principle

NCT01326299
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Carbohydrate placebo, Nutritional ingredient, #1 Nutritional ingredient +Fiber, #2 Nutritional ingredient + Fiber, #3 Nutritional ingredient + Fiber
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
21 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2011 · Synced Oct 20, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Pre-Run Nutritional Supplements During a Fixed-Pace 5 km Treadmill Run

NCT07854223
View directory record Official record
Conditions
Exercise Physiology, Nutritional Supplementation
Interventions
Caffeine, L-Citrulline, Exogenous Ketone (Beta-Hydroxybutyrate), placebo beverage
Dietary Supplement · Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

NCT04935359
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
NIS793, Nab-paclitaxel, Gemcitabine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Fayetteville, Arkansas • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Withdrawn Phase 2 Interventional

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

NCT01992276
View directory record Official record
Conditions
Influenza
Interventions
CR8020, CR6261, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Fresno, California • Stanford, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 20, 2026, 5:03 PM EDT
Not yet recruiting Not applicable Interventional

Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells - Intensive Care Unit

NCT07811180
View directory record Official record
Conditions
Glucose, Metabolism, Isotope Labeling, Immune System and Related Disorders, Critical Illness, Intensive Care Unit (ICU), Sepsis
Interventions
13C6-Glucose
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increased Protein at Breakfast for Weight Management in Overweight Adolescents

NCT03146442
View directory record Official record
Conditions
Obesity, Adolescent
Interventions
Breakfast
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
13 Years to 21 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of KH-1 for Stimulating Autophagy in Non-diabetic Adults With Elevated Blood Glucose Concentration

NCT06445569
View directory record Official record
Conditions
PreDiabetes, Aging
Interventions
KH-1, Placebo
Dietary Supplement · Other
Lead sponsor
Kalin Health, LLC
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 20, 2026, 5:03 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers

NCT05159427
View directory record Official record
Conditions
Human Gastrointestinal Physiology Data
Interventions
Glucotrol XL 5Mg Extended-Release Tablet, Glipizide ER 5 MG 24 HR Extended Release Oral Tablet, Rifaximin 200Mg Tab, 13C6-Glipizide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Stable Isotopes- Adults With Obesity

NCT07020741
View directory record Official record
Conditions
Obese Patients (BMI ≥ 30 kg/m²), Glucose Metabolism, Protein Metabolism
Interventions
Indispensable Amino Acid Oxidation, Stable Isotope Oral Glucose Tolerance Test
Procedure
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
19 Years to 59 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis

NCT00612014
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
5% dextrose in water, TZP-101
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
San Francisco, California • Anderson, Indiana • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2012 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model

NCT02371668
View directory record Official record
Conditions
H1N1 Influenza Healthy Volunteers
Interventions
CR6261, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 20, 2026, 5:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03745326
View directory record Official record
Conditions
Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL), EKG, CT, MRI, PET, Chest x-ray, Photography
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Not yet recruiting Phase 2 Interventional

Rapid Rehydration for Severe Hypernatremia

NCT07783191
View directory record Official record
Conditions
Hypernatremia
Interventions
Intravenous Dextrose 5% solution
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007

NCT00595673
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PB127 for injectable suspension
Drug
Lead sponsor
Point Biomedical
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
19
States / cities
Scottsdale, Arizona • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2008 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

GLOW Study: Effects of Triple Protein in Women

NCT07526571
View directory record Official record
Conditions
Healthy Women
Interventions
Triple protein support, Placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653
View directory record Official record
Conditions
Crohn's Disease
Interventions
abatacept, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 20, 2026, 5:03 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Dynamic Connectivity Under Metabolic Constraints

NCT04840095
View directory record Official record
Conditions
Insulin Resistance, Healthy, Diet Modification, Aging
Interventions
Ketones, Glucose
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
2
States / cities
Charlestown, Massachusetts • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 20, 2026, 5:03 PM EDT